



Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 072827-1905	SERIAL NO. 09/990,405
 <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		APPLICANT Alan Mueller, et al.	
		FILING DATE 11/21/2001	GROUP ART UNIT TBA

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	4,314,081	2/2/82	Molloy, et al.	1	1	1/10/74
	A2	4,626,549	12/2/86	Molloy, et al.	1	1	3/31/86

RECEIVED




OCT 15 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A3	Baldessarini, R. J., "Drugs and the Treatment of Psychiatric Disorders," in Goodman & Gilman's <u>The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Ed. Chapt. 19, McGraw-Hill (1996).
	A4	Brown, H. C., et al., "Chiral Synthesis via Organoboranes...", <u>J. Org. Chem.</u> <b>53</b> (13):2916-2920 (1988).
	A5	Brown, N. L., et al., "The Effects of Some Slow Channel Blocking Drugs on High Affinity Serotonin Uptake by Rat Brain Synaptosomes," <u>Eur. J. Pharmacol.</u> , <b>123</b> (1):161-165 (1986).
	A6	D'Amato, R. J., et al., "Selective Labeling of Serotonin Uptake Sites in Rat Brain by [ <sup>3</sup> H]Citalopram Contrasted to Labeling of Multiple Sites by [ <sup>3</sup> H]Imipramine," <u>J. Pharmacol. Exp. Ther.</u> , <b>242</b> :364-371 (1987)
	A7	Fieser and Fieser, <u>Reagents for Organic Synthesis</u> , Vol. 1, Wiley and Sons, (1967).

EXAMINER

WILLIAM R. A. JARVIS  
PRIMARY EXAMINER

DATE CONSIDERED

1/8/03

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 072827-1905	SERIAL NO. 09/990,405
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		APPLICANT Alan Mueller, et al.	
		FILING DATE 11/21/2001	GROUP ART UNIT TBA
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)			
A8	Gennaro, A. R., "Biotechnology and Drugs," in <u>Remington's Pharmaceutical Sciences</u> , 18 <sup>th</sup> ed., Mack Publishing Co., Easton, PA, Vol. 2, Chpt. 74:1418-1419, 1431 (1990).		
A9	Gennaro, A. R., <u>Remington's Pharmaceutical Sciences</u> , 19 <sup>th</sup> ed., Mack Publishing Co., Easton, PA, Chpt. 83:1457-1462 (1995)		
A10	Javitch, J. A., et al., "[ <sup>3</sup> H]Mazindol Binding Associated with Neuronal Dopamine and Norepinephrine Uptake Sites," <u>Molec. Pharmacol.</u> , 26(1):35-44 (1984).		
A11	Langer, S. Z., et al., "High-Affinity [ <sup>3</sup> H]DMI Binding is Associated with Neuronal Noradrenaline Uptake in the Periphery and the Central Nervous System," <u>Eur. J. Pharmacol.</u> , 72(4):423-424 (1981).		
A12	Lowry, O. H., et al., "Protein Measurement with the Folin Phenol Reagent," <u>J. Biol. Chem.</u> 193(1):265-275 (1951).		
A13	Madras, B. K., et al., "Cocaine Receptors Labeled by [ <sup>3</sup> H]2 $\beta$ -Carbomethoxy-3 $\beta$ -(4-fluorophenyl)tropane," <u>Molec. Pharmacol.</u> , 36(4):518-524 (1989).		
A14	Mitsunobu, O. et al., "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products," <u>Synthesis</u> 1:1-28 (1981).		
A15	Parks, T. N., et al., "Modulation of N-methyl-D-aspartate Receptor-mediated Increases in Cytosolic Calcium in Cultured Rat Cerebellar Granule Cells," <u>Brain Res.</u> 552(1):13-22 (1991).		
A16	Pavia, Michael, et al., "Structure-Activity Studies on Benzhydrol-Containing Nipecotic Acid and Guvacine Derivatives as Potent, Orally-Active Inhibitors of GABA Uptake," <u>J. Med. Chem.</u> , 35(22):4238-4248 (1992).		
A17	Porsolt, R. D., et al., "Behavioural Despair in Mice: A Primary Screening Test for Antidepressants," <u>Arch. Int. Pharmacodyn.</u> 229:327-335 (1977).		
A18	Porsolt, R. D., et al., "Behavioural Despair in Rats: A New Model Sensitive to Antidepressant Treatments," <u>Eur. J. Pharmacol.</u> 47(4):379-391 (1978).		
A19	Raisman, R., et al., "High-Affinity [ <sup>3</sup> H]Desipramine Binding in the Peripheral and Central Nervous System: A Specific Site Associated with the Neuronal Uptake of Noradrenaline," <u>Eur. J. Pharmacol.</u> , 78(3):345-351 (1982)		
A20	Skolnick, P., "Antidepressants New Pharmacological Strategies," <u>National Institutes of Health</u> , Bethesda, MD, (1998). *		
A21	Steru, L., et al., "The Automated Tail Suspension Test: A Computerized Device Which Differentiates Psychotropic Drugs," <u>Prog. Neuro-Psychopharmacol. Biol Psychiatry</u> 11:659-671 (1987).		
A22	Vejdšek, et al., "Potential Antiparkinsonic Agents: Synthesis and Pharmacology of Some 4-Fluoro-4'-Halogenobenz-Hydryl 2-(N,N-Disubstituted Amino)Ethyl Ethers," <u>Collect. Czech. Chem. Commun.</u> 49(11):2649-2660 (1984).		
A23	Williams, K., et al., "Effects of Polyamines on the Binding of [ <sup>3</sup> H]MK-801 to the N-Methyl-D-aspartate Receptor: Pharmacological Evidence for the Existence of a Polyamine Recognition Site," <u>Mol. Pharmacol.</u> : 36:575-581 (1989).		